Translate Bio, Inc. (TBIO:OTC) closed at $0.039 on October 22, 2026, unchanged on the day. The stock trades 74.3% below its 52-week high of $0.150 and 38,500.0% above its 52-week low of $0.000. Translate Bio, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Find more stocks like TBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.